Chen Y.Progress in lung cancer treatment.Oncol Transl Med,2015,1:3-4.. 2015.Chen Y. Progress in lung cancer treatment. Oncol Transl Med, 2015, 1: 3-4.
Current attempts have focused on target therapy in lung ... S Jafari 被引量: 0发表: 2020年 Progress in lung cancer treatment Lung cancer is the most common cause of cancer-related death in China.In recent years,the achievements in the fight against lung cancer have been fruitful... Y Che...
Lung cancer is one of the major causes of cancer-related deaths. Lung cancer mortality figures argue powerfully for new approaches to control this disease. The term chemoprevention can be defined as the use of specific natural or synthetic chemical agents to reverse, suppress, or prevent premalig...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
small cell lung cancerstagingprognostic factorsThe two-stage system introduced by the Veterans' Affairs Lung Study Group continues to be widely utilized in small-cell lung cancer (SCLC), mainly because of its simplicity and clinical utility. Approximately one third of patients with SCLC present with...
AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort J. Clin. Oncol. (2015) Julie Brahmer et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell...
Lung cancer: diagnosis, staging and treatment Lung cancer is the most common malignancy worldwide and carries a high mortality rate. The risk of developing lung cancer is strongly associated with smoki... E Teh,E Belcher - 《Surgery》 被引量: 10发表: 2014年 Lung cancer: diagnosis, staging,...
The TNM staging of lung cancer which is now widely used in clinic was formally proposed in 1997. It has played quite an important role in directing the diagnosis and treatment of lung cancer as well as the clinical research in the past decade. However,at the same time,there are some insuf...
Recent progress in the treatment paradigm for EGFR-mutant non—small cell lung cancer (NSCLC) includes the FDA’s frontline approval of osimertinib (Tagrisso) and priority review designation for dacomitinib, both of which have demonstrated longer progression-free survival (PFS) and overall survival (...
(论文)小细胞肺癌的综合治疗进展 the treatment progress of small cell lung cancer.下载积分:1500内容提示:实用肿瘤学杂志摇 圆园员圆 年第 圆远 卷第 员 期总第 员员苑 期 远苑 小细胞肺癌的综合治疗进展徐建宇员 摇 综述摇 徐向英员, 摇 审校 圆 摇 【 摘要】 基于铂类的化疗方案联合胸部放疗已成为...